Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FEMASYS INCFEMY · Entity 7510 | Director | June 21, 2023 | June 23, 2023 |
| Inotiv, Inc.BASI · Entity 29609 | Director | September 10, 2019 | September 11, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FEMASYS INC
Report date June 21, 2023 · Filed June 23, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.57 · Expires 2033-06-21 | Direct | 8,500 |
Reported balance
After 2023-06-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-21 · Grant · Acquired 8,500 · Balance 8,500 F1: The shares underlying the stock option vest one year from the date of grant, assuming continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the stock option vest one year from the date of grant, assuming continued service.
Inotiv, Inc.
Report date September 10, 2019 · Filed September 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
After 2019-09-10 transaction · row 1
1 source rowRow 1 · 2019-09-10 · Purchase · Acquired 10,000 · Balance 10,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 21, 2023 Filed Jun 23, 2023 20:15 UTC | FEMASYS INC FEMY · Entity 7510 | GrantStock Option (Right to Buy) · Derivative | 8,500 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001140361-23-031164 · form4.xml · derivative · entry 1 Perrow Wendy · CIK 0001660814 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2033-06-21 F1 · derivative.exercise_date: The shares underlying the stock option vest one year from the date of grant, assuming continued service. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 22:19 UTC | FEMASYS INC FEMY · Entity 7510 | GrantStock Option (Right to Buy) · Derivative | 8,500 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001140361-22-022653 · form4.xml · derivative · entry 1 Perrow Wendy · CIK 0001660814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,500 Underlying: Common Stock · 8,500 shares Expires 2032-06-08 F1 · derivative.exercise_date: The shares underlying the stock option vest one year from the date of grant, assuming continued service. Read SEC document |
| January 25, 2022 Filed Jan 28, 2022 02:10 UTC | FEMASYS INC FEMY · Entity 7510 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $3.03 | $0.00 |
DisclosureSEC source: 0001140361-22-002954 · form4.xml · derivative · entry 1 Perrow Wendy · CIK 0001660814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2032-01-25 F1 · shares: Represents stock options granted pursuant to the Issuer's 2021 Equity Incentive Plan. F2 · derivative.exercise_date: The shares underlying the stock options vest equally in installments over 3 years beginning on January 25, 2022. Read SEC document |
| September 10, 2019 Filed Sep 11, 2019 20:18 UTC | Inotiv, Inc. BASI · Entity 29609 | PurchaseCommon Shares | 10,000 | $3.62 | $36,200.00 |
DisclosureSEC source: 0001179110-19-010235 · edgar.xml · nonDerivative · entry 1 Perrow Wendy · CIK 0001660814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| February 08, 2019 Filed Feb 12, 2019 21:46 UTC | Inotiv, Inc. BASI · Entity 29609 | GrantDirector Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001179110-19-001765 · edgar.xml · derivative · entry 1 Perrow Wendy · CIK 0001660814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2029-02-08 F1 · derivative.exercise_date: The option becomes exercisable with respect to 40% of the shares on the first anniversary of the date of grant and with respect to an additional 30% of the shares on each of the second anniversary and the third anniversary of the date of grant, respectively. Read SEC document |
| October 27, 2017 Filed Oct 31, 2017 21:04 UTC | Inotiv, Inc. BASI · Entity 29609 | GrantDirector Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001179110-17-013597 · edgar.xml · derivative · entry 1 Perrow Wendy · CIK 0001660814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2025-10-27 F1 · derivative.exercise_date: The option will vest in three installments of 40%, 30% and 30%, respectively, on each of the first three anniversaries of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.